ALENTIS THERAPEUTICS
Alentis Therapeutics discovers and develops novel medications to treat advanced liver diseases.
ALENTIS THERAPEUTICS
Industry:
Biotechnology Therapeutics
Founded:
2019-01-01
Address:
Basel, Basel-Stadt, Switzerland
Country:
Switzerland
Website Url:
http://www.alentis.ch
Total Employee:
11+
Status:
Active
Total Funding:
184.02 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro Apple Mobile Web Clips Icon Google Font API WordPress Font Awesome Organization Schema Sitelinks Search Box Yoast WordPress SEO Plugin
Similar Organizations
Bright Peak Therapeutics
Bright Peak is a biotech company that develops a portfolio of immunotherapies for the treatment of cancer and autoimmune diseases.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Myeloid Therapeutics
Myeloid Therapeutics is an immunology company focused on combining immunologic insights with cutting-edge technologies.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
VintaBio
VintaBio is a life sciences company that offers cell and gene therapy manufacturing services.
Current Advisors List
Current Employees Featured
Founder
Investors List
Innosuisse
Innosuisse investment in Grant - Alentis Therapeutics
Schroders Capital
Schroders Capital investment in Series C - Alentis Therapeutics
Pureos Bioventures
Pureos Bioventures investment in Series C - Alentis Therapeutics
Bpifrance
Bpifrance investment in Series C - Alentis Therapeutics
RA Capital Management
RA Capital Management investment in Series C - Alentis Therapeutics
Novo Holdings
Novo Holdings investment in Series C - Alentis Therapeutics
Jeito Capital
Jeito Capital investment in Series C - Alentis Therapeutics
Morningside Venture Investments
Morningside Venture Investments investment in Series B - Alentis Therapeutics
Bpifrance
Bpifrance investment in Series B - Alentis Therapeutics
HTGF | High-Tech Gruenderfonds
HTGF | High-Tech Gruenderfonds investment in Series B - Alentis Therapeutics
Key Employee Changes
Official Site Inspections
http://www.alentis.ch Semrush global rank: 4.75 M Semrush visits lastest month: 1.93 K
- Host name: linux96.curanet.dk
- IP address: 94.231.106.215
- Location: Denmark
- Latitude: 55.7123
- Longitude: 12.0564
- Timezone: Europe/Copenhagen
More informations about "Alentis Therapeutics"
Alentis Therapeutics AG - Swiss Biotech
Alentis develops breakthrough treatments for fibrotic diseases. ... Unlike most therapies Alentis’ approach aims at a direct reversal of disease progression. https://alentis.ch/ [email protected]; Location. Hegenheimermattweg 167A, 4123 …See details»
Team - Alentis Therapeutics
Team Roberto IaconeChief Executive Officer Roberto Iacone joined Alentis in 2020, bringing over 15+ years of life science industry experience.Roberto is a physician-scientist and a serial …See details»
About Alentis Therapeutics
About Alentis Therapeutics The Claudin-1 Company Alentis is the leading biotech company developing anti-Claudin-1 therapies. Claudin-1 is an extraordinary target that plays a key role …See details»
Alentis Therapeutics AG Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Alentis Therapeutics AG of Allschwil, BASEL-LAND. Get the latest business insights from Dun & …See details»
Alentis Therapeutics: Contact Details and Business Profile
For more information, please visit us at www.alentis.ch or write to: [email protected] View Top Employees from Alentis Therapeutics Website: https://alentis.ch Employees: 59 (26 on …See details»
Alentis Therapeutics - Crunchbase Company Profile
Alentis Therapeutics, the CLDN1 company, is a clinical-stage biotech investigating novel therapeutics for CLDN1+ cancers. Alentis is the pioneering business in the use of anti-CLDN1 ADCs and antibodies to modify and …See details»
Alentis Therapeutics - SIP Basel Area
Alentis is using its portfolio of unique monoclonal antibodies that are highly selective for exposed and non-junctional Claudin-1. Claudin-1 a previously unexploited target that plays a key role in …See details»
Alentis Therapeutics - VentureRadar
Website: https://alentis.ch/ Develops innovative CLDN1-targeted therapies to combat solid tumors and organ fibrosis, enhancing treatment options in oncology and fibrosis sectors. ... IL-11 is …See details»
Alentis Therapeutics | LinkedIn
Alentis Therapeutics | 9.105 Follower:innen auf LinkedIn. We develop breakthrough treatments for Claudin1-positive tumors and organ fibrosis | Alentis Therapeutics, the Claudin-1 (CLDN1) …See details»
Alentis Therapeutics AG - top100startup.ch
04.01.2022 Alentis Therapeutics launches first-in-human clinical studies (startupticker.ch) 16.06.2021 USD67 million for Alentis Therapeutics (startupticker.ch) 15.01.2021 Five …See details»
Board of Directors - Alentis Therapeutics
Board of Directors Luca Santarelli, MDChair Dr. Santarelli has more than 20 years of experience in academic and pharmaceutical R&D, spanning the value chain from discovery research to …See details»
Alentis Therapeutics AG - startupticker.ch
Jul 10, 2024 Alentis Therapeutics AG Alentis Therapeutics, the Claudin-1 company, is a clinical-stage biotech developing breakthrough treatments for Claudin-1 positive tumors and organ …See details»
About ALENTIS THERAPEUTICS AG | DxMultiomics
Alentis Therapeutics, the CLDN1 company, is a clinical-stage biotech developing breakthrough treatments for CLDN1+ tumors and organ fibrosis. Log In. Sign Up. ALENTIS …See details»
Success story Alentis - BaseLaunch
Alentis was founded in 2018 and was financed, incubated and built in close collaboration between Prof. Thomas Baumert, the scientific founder of Alentis and the team of BaseLaunch. The …See details»
Alentis Appoints Jonathan Freve CFO
Sep 3, 2024 Jon brings more than 25 years of financial experience in the biotech sector Basel, Switzerland – Sept 3, 2024, Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology …See details»
Alentis Therapeutics - Craft
Alentis Therapeutics is a company that discovers and develops medications to treat liver diseases such as liver fibrosis, cirrhosis, and cancer. The company develops platform technologies and …See details»
Alentis Therapeutics starts their first-in-human clinical trial
Jan 6, 2022 Basel, Switzerland., 04 January 2022 — Alentis Therapeutics, AG today announced it has dosed the first cohort of healthy participants in a first-in-human Phase 1 clinical trial of …See details»
Alentis Therapeutics Appoints Dr. Luigi Manenti as Chief Medical ...
Basel, Switzerland – 5 January 2023 Alentis Therapeutics (“Alentis” or “the Company”), the biotechnology company developing breakthrough treatments for organ fibrosis and CLDN1+ …See details»
Careers - Alentis Therapeutics
Careers Work at Alentis We are a fast-growing biotech on a mission to develop much-needed new medicines for cancer and fibrosis. Our carefully chosen team values collaboration, hard work …See details»